Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.34 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.33 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.32 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.31 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.31 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA9 | Q16790 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL215571 | 1.00 | TSHR (0.46) | TSHRHCAR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL406007 | 1.00 | TSHR (0.46) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL769926 | 0.97 | — | — | |
| SCHEMBL215572 | 0.97 | — | — | |
| SCHEMBL4269578 | 0.97 | — | — | |
| SCHEMBL27315313 | 0.94 | TSHR (0.46) | TSHRHCAR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL21612233 | 0.92 | TSHR (0.43) | TSHRHCAR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL3926493 | 0.92 | TSHR (0.43) | TSHRHCAR2CA12CA1CA2 | |
| Methylene Chloride SCHEMBL28185523 | 0.91 | LMNA (0.40) | TSHRHCAR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL28144996 | 0.89 | TSHR (0.37) | TSHRHCAR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112630314-B | Separation method of L-alanine isopropyl ester hydrochloride and enantiomer thereof | 天地恒一制药股份有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-115015445-A | Detection and analysis method of L-alanine isopropyl ester hydrochloride and isomer thereof | 浙江美诺华药物化学有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-112679544-A | Preparation method of tenofovir alafenamide fumarate enantiomer | 天地恒一制药股份有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-112630314-A | Separation method of L-alanine isopropyl ester hydrochloride and enantiomer thereof | 天地恒一制药股份有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-111303210-A | Preparation method of propane fumarate tenofovir isomer impurity | 江苏海悦康医药科技有限公司 | 2020-06-19 | — | — | CN | claimed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-2970357-B1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118480070-A | Preparation and application of spiro compound with blood pressure reducing effect | 山东如至生物医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024147408-A1 | (R,RP)-ISOMER OF 2'-FLUORO-6'-METHYLENE CARBOCYCLIC ADENOSINE MONOPHOSPHATE PRODRUG, AND USE THEREOF | IMMUNODESIGNERS CO., LTD. (KR) | 2024-07-11 | — | — | WO | disclosed |
| CN-116874485-B | Preparation and application of spiro compound with blood pressure reducing effect | 山东如至生物医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-3334743-B1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-7608599-B2 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| EP-0186292-B1 | TRIPEPTIDES AND SWEETENING AGENTS CONTAINING THE SAME | AJINOMOTO CO., INC. (JP) | 1990-05-16 | — | — | EP | disclosed |
| US-4780528-A | Tripeptides and sweetening agents containing the same | AJINOMOTO CO., INC. (JP) | 1988-10-25 | — | — | US | disclosed |
| EP-0195047-A4 | AMINOMALONYL ALANINE COMPOUNDS AND USE AS DIETARY SWEETENERS. | RES TRIANGLE INST (US) | 1988-05-31 | — | — | EP | disclosed |
| EP-0195047-A1 | AMINOMALONYL ALANINE COMPOUNDS AND USE AS DIETARY SWEETENERS | RESEARCH TRIANGLE INSTITUTE (US) | 1986-09-24 | — | — | EP | disclosed |
| EP-0186292-A2 | Tripeptides and sweetening agents containing the same | AJINOMOTO CO., INC. (JP) | 1986-07-02 | — | — | EP | disclosed |
| WO-1986001690-A1 | AMINOMALONYL ALANINE COMPOUNDS AND USE AS DIETARY SWEETENERS | RESEARCH TRIANGLE INSTITUTE (US) | 1986-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | CA2 4632/4885PPARG 4192/4885GRIN2D 4747/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | CA2 3731/4885PPARG 3539/4885GRIN2D 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.